Efficacy of antidepressants in adultsBMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7509.155 (Published 14 July 2005) Cite this as: BMJ 2005;331:155
Posted as supplied by the author
w1. Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Herbert et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomisde controlled trials. BMJ 2005;330:396-399.
w2. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 2005;330:385-8.
w3. Agency for Health Care Policy and Research Treatment of depression: newer
pharmacotherapies. San Antonio, Texas: Texas University Health Science Center, 1999.
w4. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants : Meta-analysis of dose-effect relationships in randomised clinical trials. British Journal of Psychiatry 1999;174:297-303.
w5. Bech P, Cialdella P, Haugh MC, Birkett MA, Hours A, Boissel JP, Tollefson GD. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. British Journal of Psychiatry 2000;176:421-428.
w6. Elkin I, Shea T, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, Leber WR, Docherty JP, Fiester SJ, Parloff MB. National Institute of Mental Health treatment of depression collaborative research program. Archives of General Psychiatry 1989;46:971-982.
w7. Paykel ES, Hollyman JA, Freeling P, Sedgwick P. Predictors of therapeutic benefit from amitriptyline in mild depression : general practice placebo-controlled trial. Journal of Affective Disorders 1988;14:83-95.
w8. Greenberg RP, Fisher S. Mood-mending medicines: Probing drug, psychotherapy and placebo solutions. In Greenberg RP, Fisher S (Editors), From Placebo to Panacea. P 115-172. New York: John Wiley & Sons, 1997.
w9. Antonuccio DO, Danton WG, DeNelsky GY, Greenberg RP, Gordon JS. Raising questions about antidepressants. Psychotherapy and Psychosomatics 1999;68:3-14.
w10. Moncrieff J. Are antidepressants over-rated? A review of methodological problems in antidepressant trials. JNMD 2001;189:288-295.
w11. Medical Research Council. Clinical trial of the treatment of depressive illness. BMJ 1965;1:881-886.
w12. Raskin A, Schulterbrandt JG, Reatig N, Chase C, McKeon JJ. Differential response to chlorpromazine, imipramine and placebo. Archives of General Psychiatry 1970;23:164-173.
w13. Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus. Association between antidepressant prescribing and suicide in Australia, 1991-2000:trend analysis. BMJ 2003; 326:1008-1011.
w14. Grunebaum MF, Ellis SP, Li S, Oquendo MA, Mann JJ. Antidepressants and suicide risk in the United States 1985-1999. J Clin Psychiatry 2004; 65:1456-62
w15. Gunnel D, Ashby D. Antidepressants and suicide: what is the balance of benefit and harm. BMJ 2004; 329:34-38.
w16. Murphy GE, Wetzel RD. Suicide risk by birth cohort in the United States, 1949 to 1974. Arch Gen Psychiatry 1980;37:519-23
w17. Draper BM. Decline in older suicides in Australia was much greater before antidepressants were introduced. BMJ Rapid Responses 2003; bmj.bmjjournals.com/eletters/326/7397/1008.
w18. Walsh D. Antidepresasants and suicide in Ireland. BMJ Rapid Responses 2004; bmj.bmjjournals.com/eletters/329/7456/34#67931. Statistics available courtesy of Irish Association of Suicidology at http://www.ias.ie/content.cfm?page=151&parent=150&CFID=269762&CFTOKEN=54322293.
w19. Storosum JG, van Zwieten BJ, van den brink W, gersons BP, broekmans AW. Suicide risk in placebo controlled studies of major depression. Am J Psychiatry 2002; 158:1271-75.
w20. Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants and placebo: analysis of FDA reports. Am J Psychiatry 2003; 160:790-92.
- This Week In The BMJ Published: 14 July 2005; BMJ 331 doi:10.1136/bmj.331.7509.0-e
- Editorial Published: 03 February 2005; BMJ 330 doi:10.1136/bmj.330.7486.267
- Education And Debate Published: 14 July 2005; BMJ 331 doi:10.1136/bmj.331.7509.158
- Review Published: 18 August 2005; BMJ 331 doi:10.1136/bmj.331.7514.462-a
- Nonconscious activation of placebo and nocebo pain responses
- Can a 'true' effect be built on a 'wrong' model?
- A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder
- What we talk about when we talk about depression: doctor-patient conversations and treatment decision outcomes
- Assessing the 'true' effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model
- Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data
- Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis
- 'What would you do if you were me, doctor?': randomised trial of psychiatrists' personal v. professional perspectives on treatment recommendations
- The increased use of antidepressants has contributed to the worldwide reduction in suicide rates
- Making the best use of available evidence: the case of new generation antidepressants: A response to: Are all antidepressants equal?
- To prescribe or not to prescribe?
- Do antidepressants work? A commentary on "Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration" by Kirsch et al
- Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials
- Regulatory policies on medicines for psychiatric disorders: is Europe on target?
- Author's reply
- Ethical issues in psychopharmacology.
- Forensic database study suggests selective serotonin reuptake inhibitors do not increase the risk of suicide in people taking antidepressants
- Hit parade
- Why stop at antidepressants?